Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

531
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
531
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

605
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
605
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

733
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
733
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.4K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

916
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
916
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

755
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
755

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What Makes a Great Manuscript?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Noninvasive Predictive Model for Rapid Hemodynamic Optimization During Mechanical Circulatory Support.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

The Basophilic Fringe: A Case Report of Intestinal Spirochetosis in a Patient With Chronic Diarrhea.

Cureus·2026
Same author

Circulatory arrest time above 30 min have significantly detrimental effects on the outcomes of type a aortic dissection repair.

Journal of cardiothoracic surgery·2026
Same author

Temporary circulatory support for cardiogenic shock: technology overview and limitations.

Expert review of medical devices·2026
Same author

Computational hemodynamic assessment of axillary and femoral artery perfusion for extracorporeal left ventricular assist device.

Frontiers in cardiovascular medicine·2025

Related Experiment Video

Updated: Mar 22, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K

Limitations to Chronic Right Ventricular Assist Device Support.

Jamshid H Karimov1, Gengo Sunagawa1, David Horvath1

  • 1Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

The Annals of Thoracic Surgery
|April 24, 2016
PubMed
Summary

Right ventricular failure (RVF) is a common complication in patients with left ventricular assist devices (LVADs), yet treatment options remain limited. This review explores RVF, device challenges, and potential implantable ventricular assist devices (VADs) for RV support.

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K

Related Experiment Videos

Last Updated: Mar 22, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.5K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Right ventricular failure (RVF) is a significant clinical issue, affecting 5-50% of patients with left ventricular assist devices (LVADs).
  • Current treatment strategies and device innovations for RVF have not kept pace with advancements in left ventricular assist device (LVAD) technology.
  • There is a critical need for novel technologies to address RVF and ensure adequate long-term circulatory support.

Purpose of the Study:

  • To highlight the clinical significance and physiological implications of right ventricular failure (RVF).
  • To examine the device-related constraints impacting treatment options for RVF.
  • To review implantable ventricular assist devices (VADs) that are suitable for right ventricular (RV) support.

Main Methods:

  • Literature review focusing on right ventricular failure (RVF) in the context of ventricular assist device (VAD) therapy.
  • Analysis of current device limitations and technological gaps in RV support.
  • Exploration of existing and emerging implantable VADs for RV application.

Main Results:

  • Right ventricular failure (RVF) presents complex physiological challenges and occurs frequently in LVAD patients.
  • Significant technological and design constraints limit the efficacy of current devices for RV support.
  • Several implantable VADs show potential for RV application, though long-term data is often limited.

Conclusions:

  • Addressing right ventricular failure (RVF) requires dedicated technological advancements beyond current left ventricular assist device (LVAD) capabilities.
  • Overcoming device constraints is crucial for developing effective long-term RV support solutions.
  • Further research and development of specialized implantable VADs are essential for improving outcomes in patients with RVF.